^
    Apply
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (NCT06023641)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2024
    Primary completion :
    10/01/2034
    Completion :
    10/01/2037
    TP53 • FOXO1 • MYOD1
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)
    Phase 1/2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/09/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EWSR1 • FLI1
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/31/2024
    Primary completion :
    02/28/2026
    Completion :
    12/31/2026
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma (ARST2031) (NCT04994132)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/14/2021
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    FOXO1
    |
    cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma (NCT05304585)
    Phase 3
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/04/2022
    Primary completion :
    06/30/2030
    Completion :
    06/30/2030
    FOXO1
    |
    cyclophosphamide • vincristine • dactinomycin
    VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors (NCT04796012)
    Phase 1/2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    PD-L1
    |
    Tecentriq (atezolizumab) • temozolomide • irinotecan • vincristine
    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/23/2017
    Primary completion :
    09/30/2024
    Completion :
    10/08/2025
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (ARST1431) (NCT02567435)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/01/2016
    Primary completion :
    06/30/2023
    Completion :
    10/16/2025
    FOXO1 • PAX3 • PAX7
    |
    cyclophosphamide • irinotecan • Torisel (temsirolimus) • vincristine • vinorelbine tartrate • dactinomycin
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/31/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (PEPN2112) (NCT05071209)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/22/2021
    Primary completion :
    09/30/2024
    Completion :
    11/22/2025
    BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3
    |
    PAX3-FOXO1 fusion
    |
    elimusertib (BAY 1895344)
    International PPB/DICER1 Registry (NCT03382158)
    Phase N/A
    Children's Hospitals and Clinics of Minnesota
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/06/2016
    Primary completion :
    12/06/2030
    Completion :
    12/06/2035
    DICER1
    |
    doxorubicin hydrochloride • cyclophosphamide
    Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma (TARGET-RT) (NCT06796543)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Not yet recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/01/2028
    Completion :
    03/01/2030
    EFS
    Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (NCT03709680)
    Phase 1/2
    Pfizer
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    05/24/2019
    Primary completion :
    06/24/2024
    Completion :
    02/25/2025
    EWSR1 • FUS
    |
    Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/28/2017
    Primary completion :
    09/30/2023
    Completion :
    10/01/2024
    PTEN • TSC2 • TSC1
    |
    PTEN expression • TSC1 mutation • TSC2 mutation
    |
    samotolisib (LY3023414)
    Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/13/2018
    Primary completion :
    03/31/2023
    Completion :
    09/22/2024
    RB1
    |
    Ibrance (palbociclib)
    Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/08/2017
    Primary completion :
    06/30/2022
    Completion :
    09/22/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib)
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04715191)
    Phase 1
    Baylor College of Medicine
    Not yet recruiting
    Last update posted :
    05/06/2024
    Initiation :
    07/03/2024
    Primary completion :
    08/01/2026
    Completion :
    07/03/2041
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous
    B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2040
    CD276
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (NCT04530487)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    08/19/2020
    Primary completion :
    05/09/2025
    Completion :
    05/09/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion
    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-01) (NCT03618381)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/18/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2040
    EGFR
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Molecular-Guided Therapy for Childhood Cancer (NCT02162732)
    Phase N/A
    Giselle Sholler
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    07/08/2014
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    MYCN
    |
    MYCN amplification
    NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) (NCT01386619)
    Phase 1/2
    University Hospital, Basel, Switzerland
    Completed
    Last update posted :
    03/19/2024
    Initiation :
    01/01/2004
    Primary completion :
    03/01/2011
    Completion :
    03/01/2011
    NCAM1
    Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (NCT02100891)
    Phase 2
    Monica Thakar
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    03/20/2013
    Primary completion :
    06/08/2020
    Completion :
    07/15/2020
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NCT01505569)
    Phase N/A
    Masonic Cancer Center, University of Minnesota
    Completed
    Last update posted :
    02/26/2024
    Initiation :
    10/20/2011
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    MYCN • CD34
    |
    LDH elevation • MYCN expression
    |
    cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan
    Evolutionary Therapy for Rhabdomyosarcoma (NCT04388839)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    09/27/2020
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    FOXO1
    |
    doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients (RMS-AJA-1701) (NCT03462888)
    Phase N/A
    Centre Oscar Lambret
    Active, not recruiting
    Last update posted :
    02/09/2024
    Initiation :
    02/02/2018
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    MYOD1
    Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (NCT03496402)
    Phase N/A
    Institut Curie
    Recruiting
    Last update posted :
    02/05/2024
    Initiation :
    04/20/2018
    Primary completion :
    04/19/2027
    Completion :
    08/19/2027
    MYCN
    |
    MYCN amplification
    Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (NCT01661400)
    Phase 1
    Washington University School of Medicine
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    10/26/2012
    Primary completion :
    12/27/2023
    Completion :
    12/27/2023
    CD34
    |
    cyclophosphamide • thalidomide • cyclophosphamide intravenous
    HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    12/07/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2040
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    CREATE: Cross-tumoral Phase 2 With Crizotinib (NCT01524926)
    Phase 2
    European Organisation for Research and Treatmen...
    Completed
    Last update posted :
    12/11/2023
    Initiation :
    09/01/2012
    Primary completion :
    12/06/2017
    Completion :
    10/30/2022
    ALK • MET
    |
    Xalkori (crizotinib)
    Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (NCT06094101)
    Phase 1/2
    University Hospital Tuebingen
    Recruiting
    Last update posted :
    11/22/2023
    Initiation :
    09/19/2023
    Primary completion :
    06/01/2027
    Completion :
    09/01/2027
    CD8 • CD4
    Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    03/30/2015
    Primary completion :
    09/30/2021
    Completion :
    03/31/2023
    PD-L1 • BRAF
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02095132)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/26/2023
    Initiation :
    03/28/2014
    Primary completion :
    12/31/2020
    Completion :
    06/30/2023
    MYCN • AFP
    |
    MYCN amplification
    |
    adavosertib (AZD1775) • irinotecan
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    06/17/2021
    Primary completion :
    01/01/2025
    Completion :
    12/01/2039
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous
    Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (NCT03009201)
    Phase 1b
    OHSU Knight Cancer Institute
    Completed
    Last update posted :
    08/16/2023
    Initiation :
    03/10/2017
    Primary completion :
    10/08/2019
    Completion :
    06/30/2023
    RB1
    |
    doxorubicin hydrochloride • Kisqali (ribociclib)
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    08/08/2023
    Initiation :
    07/06/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    CD276
    |
    CD276 expression
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    12/08/2021
    Primary completion :
    02/01/2025
    Completion :
    02/01/2040
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous
    Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (NCT03478462)
    Phase 1
    Cellectar Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/17/2023
    Initiation :
    04/30/2019
    Primary completion :
    09/25/2022
    Completion :
    12/01/2024
    CD34
    |
    iopofosine I-131 (CLR 131)
    Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome (NCT00565903)
    Phase N/A
    Ashley Hill
    Completed
    Last update posted :
    03/01/2023
    Initiation :
    03/01/2005
    Primary completion :
    12/31/2018
    Completion :
    12/31/2022
    DICER1
    Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758)
    Phase 1
    Brenda Cooper, MD
    Completed
    Last update posted :
    02/20/2023
    Initiation :
    05/22/2018
    Primary completion :
    06/01/2021
    Completion :
    02/17/2023
    ABL1 • BCR • NCAM1
    |
    NCAM1 positive
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (ARST0531) (NCT00354835)
    Phase 3
    Children's Oncology Group
    Completed
    Last update posted :
    01/31/2023
    Initiation :
    12/26/2006
    Primary completion :
    12/31/2014
    Completion :
    12/31/2022
    UGT1A1 • CYP2C9
    |
    UGT1A1*1*1
    |
    cyclophosphamide • irinotecan • vincristine • dactinomycin • cyclophosphamide intravenous